Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements
Alnylam Pharmaceuticals financial statements at a glance
Alnylam Pharmaceuticals reported revenue of $3.71 billion for fiscal year 2025 (ended December 31, 2025), up 65.2% from fiscal year 2024. Net income was $313.75 million, a net margin of 8.4%, and diluted earnings per share were $2.33.
At the end of fiscal year 2025 it had total assets of $4.97 billion, total liabilities of $4.18 billion and shareholders' equity of $789.18 million, with cash and short-term investments of $2.91 billion and total debt of $1.28 billion.
Its operations brought in $524.08 million of cash; capital spending was $58.70 million, leaving free cash flow of $465.38 million.
The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.
Figures from company filings, in USD; latest fiscal year ended December 31, 2025.
Alnylam Pharmaceuticals, Inc.
Income Statement
Annual • USD
Alnylam Pharmaceuticals key figures by fiscal year
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $3.7B | $2.2B | $1.8B | $1.0B | $844.3M |
| Gross profit | $3.0B | $1.9B | $1.5B | $868.6M | $704.1M |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$861.7M | -$708.7M |
| Net income | $313.7M | -$278.2M | -$440.2M | -$1.1B | -$852.8M |
| Diluted EPS | $2.33 | – | – | – | -$7.20 |
| Total assets | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B |
| Total liabilities | $4.2B | $4.2B | $4.1B | $3.7B | $3.1B |
| Shareholders' equity | $789.2M | $67.1M | -$220.6M | -$158.2M | $588.2M |
| Cash and short-term investments | $2.9B | – | – | – | $2.4B |
| Total debt | $1.3B | $1.0B | $1.0B | $1.0B | $997.6M |
| Operating cash flow | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M |
| Capital spending | $58.7M | – | – | – | $76.4M |
| Free cash flow | $465.4M | – | – | – | -$718.1M |
In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2020.
Questions and answers
What was Alnylam Pharmaceuticals's revenue in fiscal year 2025?
$3.71 billion, up 65.2% from $2.25 billion in fiscal year 2024.
How much profit does Alnylam Pharmaceuticals make?
Alnylam Pharmaceuticals reported net income of $313.75 million for fiscal year 2025 (8.4% of revenue); operating income was $501.58 million.
How much cash and debt does Alnylam Pharmaceuticals have?
At the end of fiscal year 2025: cash and short-term investments of $2.91 billion and total debt of $1.28 billion.
What is Alnylam Pharmaceuticals's free cash flow?
$465.38 million in fiscal year 2025 (operating cash flow of $524.08 million minus capital spending of $58.70 million).
